The role of aspirin resistance in the treatment of acute coronary syndromes

Clinical Cardiology

Volumn 31, Issue 1, 2008, Pages 11-17

  Lancaster, Gilead I ^a   Jain, Hitender ^b   Zarich, Stuart W ^b  

^a BRIDGEPORT HOSPITAL   (United States)

^b NONE

Author keywords

Acute coronary syndrome; Aspirin failure; Aspirin resistance; Glycoprotein IIb IIIa receptor inhibitor; Low molecular weight heparin; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TIROFIBAN;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANALYTIC METHOD; ANALYZER; ARTICLE; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DEATH; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIGHT TRANSMISSION AGGREGOMETRY; PROGNOSIS; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ASPIRIN; CORONARY DISEASE; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; SYNDROME; TREATMENT OUTCOME;

EID: 38349099827     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20157     Document Type: Article

References (45)

1. Masoudi FA, Wolfe P, Havranek EP, Rathore SS, Foody JM, et al.: Aspirin use in older patients with heart failure and coronary artery disease. J Am Coll Cardiol 2005;46:955-962
2. Lancaster GI, Lancaster CJ, Radley D, Cohen M: Prior aspirin use in unstable angina predisposes to higher risk: the aspirin paradox. Int J Cardiol 2001;80:201-207
3. Santopinto J, Gurfinkel EP, Torres V, Marcos E, Bozovich GE, et al.: Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Am Heart J 2001;141:566-572
4. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, et al.: Prior aspirin use predicts worse outcomes in patients with non-ST-elevationacute coronary syndromes. Am J Cardiol 1999;83:1147-1151
5. Antman EM, Cohen M, Bernink PJLM, McCabe CH, Horacek T, et al.: The TIMI risk score for unstable angina/non-ST elevation MI. JAMA 2000;284:835-842
6. Braunwald E, Antman EM, Beasley JW, Robert M. Califf, Cheitlin MD, et al.: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Circulation 2002;106:1893-1900
7. Mason PJ, Jacobs AK, Freedman JE: Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005;46:986-993
8. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, et al.: Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-1311
9. Dalen JE: Apirin resistance: Is it real? Is it clinically significant? Am J Med 2007;120:1-4
10. Théroux P, Ouimet H, McCans J, Latour J-G, Joly P, et al.: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111
11. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, et al.: Combination antithrombotic therapy in unstable rest angina and non-q-wave infarction in nonprior aspirin users. Circulation 1994;89:81-88
12. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235
13. Macchi L, Christiaens L, Brabant S, Sorela N, Allalb J, Maucoc'd, Brizarda A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-49
14. Andersen K, Hurlen M, Arnesen H, Seljeflot I: Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003;108:37-42
15. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H: Aspirin non responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-66
16. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective blinded determination of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965
17. Wang JC, Aucoin-Barry D, Manuelin D, Monbouquette R, Reisman M, et al.: Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay-ASA. Am J Cardiol 2003;92:1492-1494
18. Chen W, Lee P, Ng W, Tse H, Lau C: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-1126
19. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V: Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295-301
20. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, et al.: Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973-975
21. Tantry US, Bliden KP, Gurbel PA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705-1709
22. Dalen JE: Aspirin to prevent heart attack and stroke: what's the right dose? Am J Med 2006;119:198-202
23. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403
24. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655
25. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, et al.: High frequency of aspirin resistance in patients with acute coronary syndrome Tohoku. J Exp Med 2005;207:59-64
26. Garcia-Dorado D, Théroux P, Tornos P, Sambola A, Oliveras J, et al.: Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. Circulation 1995;92:1743-1748
27. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497
28. Gore JM, Spencer FA, Goldberg RJ, Kennelly BM, Fox KAA, et al.: Use of heparins in non-ST-elevation acute coronary syndromes. Am J Med 2007;120:63-71
29. Borzak S, Cannon C, Kraft P, Douthat L, Becker RC, et al.: Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. Am J Cardiol 1998;81:678-681
30. Screiber TL, Mancina G, Bunnell P: Unstable angina and non-q-wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms. Am Heart J 1990;120:248-255
31. Ambrose JA, Weinrauch M: Thrombosis in ischemic heart disease. Arch Intern Med 1996;156:1382-1393
32. Ambrose JA: Plaque disruption and the acute coronary syndromes of unstable angina and myocardial infarction: if the substrate is similar, why is the clinical presentation different? J Am Coll Cardiol 1992;19:1653-1658
33. Giri S, Waters DD: Pathophysiology and initial management of the acute coronary syndromes. Curr Opin Cardiol 1996;11:351-360
34. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, et al.: Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992;326:287-291
35. Topol EJ: Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998;97:211-218
36. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997;337:447-452
37. Meyer BJ, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, et al.: Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin. Comparison with heparin and aspirin. Circulation 1998;97:681-685
38. Burgess JK, Chong Bh: The platelet proaggregating and potentiating effects of UFH, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 1997;58:279-285
39. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A: Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-244
40. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533
41. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
42. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized coparison of streptokinase vs tissue plasminogen activator vs antistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
43. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622
44. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Investigators, A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782
45. Antman E, Morrow DA, McCabe CH, Murphy SA, Ruda M, et al.: Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-1488